Search results
Results from the WOW.Com Content Network
Invitae (NYSE:NVTA) stock popped on investors’ radars earlier this month thanks to its nearly 277% surge in price on Aug 10. Following its latest earnings report, retail traders jumped into the ...
Invitae has seen its stock pop by 157% following 2nd-quarter earnings results. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
Raymond James has downgraded Invitae Corp (NYSE: NVTA) to Market Perform from Outperform following news of a full reset, including leadership changes and business line exits. The guidance puts ...
Invitae Corp. is a biotechnology company that was created as a subsidiary of Genomic Health in 2010 and then spun-off in 2012. [ 2 ] In 2017, Invitae acquired Good Start Genetics and CombiMatrix.
On September 29, 2005 () it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares. [8] Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests. Invitae was spun off in 2012. [9]
Invitae (NVTA) closed at $29.95 in the latest trading session, marking a +1.66% move from the prior day.
On 11 August 2021, ProPhase Labs, a diversified medical science and technology company, announced the acquisition of Nebula Genomics by its recently formed subsidiary, ProPhase Precision Medicine, Inc., for about $14.6 million in a combination of ProPhase Labs common stock and cash.
Invitae (NVTA) delivered earnings and revenue surprises of 28.81% and 0.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?